Andra AP fonden reduced its position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 15.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,100 shares of the company’s stock after selling 13,100 shares during the period. Andra AP fonden owned 0.17% of Taro Pharmaceutical Industries worth $7,743,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of TARO. Schwab Charles Investment Management Inc. raised its stake in Taro Pharmaceutical Industries by 36.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 4,850 shares of the company’s stock worth $544,000 after buying an additional 1,306 shares in the last quarter. Anchor Capital Advisors LLC raised its stake in Taro Pharmaceutical Industries by 0.4% in the second quarter. Anchor Capital Advisors LLC now owns 20,733 shares of the company’s stock worth $2,323,000 after buying an additional 77 shares in the last quarter. Sei Investments Co. raised its stake in Taro Pharmaceutical Industries by 7.7% in the second quarter. Sei Investments Co. now owns 8,372 shares of the company’s stock worth $938,000 after buying an additional 597 shares in the last quarter. Bessemer Group Inc. raised its stake in Taro Pharmaceutical Industries by 138.6% in the second quarter. Bessemer Group Inc. now owns 2,083 shares of the company’s stock worth $234,000 after buying an additional 1,210 shares in the last quarter. Finally, Eagle Global Advisors LLC bought a new stake in Taro Pharmaceutical Industries during the second quarter worth about $616,000. 16.26% of the stock is currently owned by institutional investors.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) opened at 102.66 on Friday. The firm has a 50-day moving average price of $109.76 and a 200-day moving average price of $112.65. Taro Pharmaceutical Industries Ltd. has a 52-week low of $92.28 and a 52-week high of $128.93. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of 10.45 and a beta of 0.64.

ILLEGAL ACTIVITY NOTICE: “Andra AP fonden Has $7.74 Million Position in Taro Pharmaceutical Industries Ltd. (TARO)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://theolympiareport.com/2017/08/27/andra-ap-fonden-has-7-74-million-position-in-taro-pharmaceutical-industries-ltd-taro.html.

A number of equities research analysts have issued reports on the company. BidaskClub raised Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. TheStreet raised Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a research report on Thursday, July 20th. Finally, Credit Suisse Group lowered Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research report on Tuesday, May 23rd.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.